Partnership Addresses the Analysis and Interpretation Hurdles That
Limit the Impact of Precision Medicine
Under the terms of the agreement, N-of-One and Appistry will jointly market and sell N-of-One’s interpretation services and content together with Appistry’s bioinformatics next-generation sequencing analysis solutions and services to enable a complete workflow that will yield therapeutic insights and options from raw sequencing data. Terms of the agreement were not disclosed.
“The challenges and capabilities needed to realize the promise of precision medicine are very complex, which has meant that genomics-based approaches are limited to those willing and able to make major investments in infrastructure and expertise,” said
Together, Appistry and N-of-One will target diagnostic labs, healthcare providers and other healthcare organizations that want to adopt a complete knowledge solution for precision medicine.
“We are committed to our mission of enabling precision medicine for researchers and physicians by providing outstanding molecular interpretation. Working with Appistry, a leader in transforming vast quantities of data into actionable intelligence, we are able together to meet the needs of health care organizations who are implementing and offering advanced molecular profiling services to their oncology patients,” said
A leading provider of high-performance computing and analytics for managing big data, Appistry empowers medical researchers, oncologists, and clinicians to capitalize on genomics medicine. Appistry is also the authorized provider Broad tools for next-generation sequencing analysis, making the tools easier to implement and use in for-profit settings. Learn more by visiting www.appistry.com or following us on Facebook, Twitter, and LinkedIn.
N-of-One, a leader in precision medicine for oncology, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinical insightsand therapeutic options focused on the point of care. N-of-One’s team of experts has interpreted more than 6,000 tumors for oncologists and patients worldwide, through partnerships to provide clinical interpretation for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as